Cargando…

Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry?

The prognostic significance of tumor budding in colon cancer is unequivocally documented, and the recommendations of the International Tumor Budding Consensus Conference (ITBCC) are currently the accepted basis for its assessment. Up to now, it is unknown whether the general use of a supporting cyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Benedikt, Mayr, Patrick, Ihringer, Regina, Schäfer, Eva-Maria, Jakubowicz, Elżbieta, Anthuber, Matthias, Schenkirsch, Gerhard, Schaller, Tina, Märkl, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555133/
https://www.ncbi.nlm.nih.gov/pubmed/32967382
http://dx.doi.org/10.3390/diagnostics10090730
_version_ 1783593936448651264
author Martin, Benedikt
Mayr, Patrick
Ihringer, Regina
Schäfer, Eva-Maria
Jakubowicz, Elżbieta
Anthuber, Matthias
Schenkirsch, Gerhard
Schaller, Tina
Märkl, Bruno
author_facet Martin, Benedikt
Mayr, Patrick
Ihringer, Regina
Schäfer, Eva-Maria
Jakubowicz, Elżbieta
Anthuber, Matthias
Schenkirsch, Gerhard
Schaller, Tina
Märkl, Bruno
author_sort Martin, Benedikt
collection PubMed
description The prognostic significance of tumor budding in colon cancer is unequivocally documented, and the recommendations of the International Tumor Budding Consensus Conference (ITBCC) are currently the accepted basis for its assessment. Up to now, it is unknown whether the general use of a supporting cytokeratin immunohistochemistry can improve the interobserver variability and prognostic significance. Six investigators with different levels of experience reassessed 229 cases of colon carcinoma (pT3/4, N+/−, M0) with a supporting cytokeratin immunohistochemistry. The results were compared to previous assessments, which have been performed only on H & E. Bd3 was significantly associated with the occurrence of distant metastases according to the assessments of three out of six investigators (p < 0.05). Only one single investigator reached significant results concerning the cancer specific survival (p = 0.01). The pairwise kappa values range between a poor and moderate level of agreement (range 0.17–0.45; median 0.21). In conclusion, the results show no superiority of the use of an additional cytokeratin immunohistochemistry compared to the conventional analysis on sole H & E slides. Therefore, the general supporting use of a cytokeratin immunohistochemical staining seems to be inadvisable in colon cancer in consideration of necessary resources and costs.
format Online
Article
Text
id pubmed-7555133
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75551332020-10-14 Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry? Martin, Benedikt Mayr, Patrick Ihringer, Regina Schäfer, Eva-Maria Jakubowicz, Elżbieta Anthuber, Matthias Schenkirsch, Gerhard Schaller, Tina Märkl, Bruno Diagnostics (Basel) Brief Report The prognostic significance of tumor budding in colon cancer is unequivocally documented, and the recommendations of the International Tumor Budding Consensus Conference (ITBCC) are currently the accepted basis for its assessment. Up to now, it is unknown whether the general use of a supporting cytokeratin immunohistochemistry can improve the interobserver variability and prognostic significance. Six investigators with different levels of experience reassessed 229 cases of colon carcinoma (pT3/4, N+/−, M0) with a supporting cytokeratin immunohistochemistry. The results were compared to previous assessments, which have been performed only on H & E. Bd3 was significantly associated with the occurrence of distant metastases according to the assessments of three out of six investigators (p < 0.05). Only one single investigator reached significant results concerning the cancer specific survival (p = 0.01). The pairwise kappa values range between a poor and moderate level of agreement (range 0.17–0.45; median 0.21). In conclusion, the results show no superiority of the use of an additional cytokeratin immunohistochemistry compared to the conventional analysis on sole H & E slides. Therefore, the general supporting use of a cytokeratin immunohistochemical staining seems to be inadvisable in colon cancer in consideration of necessary resources and costs. MDPI 2020-09-21 /pmc/articles/PMC7555133/ /pubmed/32967382 http://dx.doi.org/10.3390/diagnostics10090730 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Martin, Benedikt
Mayr, Patrick
Ihringer, Regina
Schäfer, Eva-Maria
Jakubowicz, Elżbieta
Anthuber, Matthias
Schenkirsch, Gerhard
Schaller, Tina
Märkl, Bruno
Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry?
title Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry?
title_full Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry?
title_fullStr Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry?
title_full_unstemmed Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry?
title_short Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry?
title_sort interobserver variability in the assessment of tumor budding in pt 3/4 colon cancer: improvement by supporting immunohistochemistry?
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555133/
https://www.ncbi.nlm.nih.gov/pubmed/32967382
http://dx.doi.org/10.3390/diagnostics10090730
work_keys_str_mv AT martinbenedikt interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry
AT mayrpatrick interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry
AT ihringerregina interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry
AT schaferevamaria interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry
AT jakubowiczelzbieta interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry
AT anthubermatthias interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry
AT schenkirschgerhard interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry
AT schallertina interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry
AT marklbruno interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry